



# Vétoquinol

a Sign of Passion

## FORCYL® - A BOOMING BRAND

Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs.

One year following the European launch of Forcyl®, a patented innovation based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection, Vétoquinol has extended the scope of its Forcyl® offering to include treatment for acute mastitis in dairy cows and two new therapeutic indications in pigs.



### Treatment of acute E.coli mastitis in dairy cows

Given its immediate anti-bacterial effect, Forcyl® acts rapidly and extremely effectively by means of a single injection. The drug also boasts a very short milking withdrawal period (48 hours) that minimizes any dairy losses. Its unique administration and optimum dose, based on the SISAAB\* concept, allow the reasonable use of antibiotics.

### Pigs, a new target

Forcyl® Swine treats both E. Coli induced diarrhea in piglets and respiratory infections in fattening pigs. The new patented Forcyl® formula is the latest SISAAB\* innovation from Vétoquinol. The single injection high dose and speed of action promote the efficacy of the treatment.

"These new product launches strengthen the company's reputation as a world expert in the scientific development of marbofloxacin", Vétoquinol CEO Matthieu Frechin explained. "The new market authorizations expand our Forcyl® product offering in Europe".

\* **SISAAB**: Single Injection Short Acting AntiBiotic

This concept, developed by Vétoquinol, is based on an increased dose of antibiotics to achieve a rapid anti-bacterial effect, thus reducing the period of treatment so as to minimize the risk of selection for resistance. It is nowadays acknowledged by vets and the scientific community thanks to numerous results already published. SISAAB is cited as a strength of Forcyl® in European market studies and is applied as the preferred use of fluoroquinolones in recommendations for using antibiotics in certain countries.

#### **About Vétoquinol**

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10<sup>th</sup> largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has 1,800 employees worldwide.

For more information: [www.vetoquinol.com](http://www.vetoquinol.com).

### **OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For more information, contact:

#### **VETOQUINOL**

Finance department

Marie-Josée AUBRY-ROTA

Tel.: 03 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

#### **KEIMA COMMUNICATION**

Investor relations

Emmanuel DOVERGNE

Tel.: 01 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

Media relations

Alix HERIARD DUBREUIL

Tel.: 01 56 43 44 62

[alix.heriard@keima.fr](mailto:alix.heriard@keima.fr)